Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Belimumab

Nature Reviews Drug Discovery volume 10, pages 335–336 (2011)Cite this article

Subjects

Abstract

In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, was approved by the US Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Smith, R. M. et al. Biological therapy for lupus nephritis — tribulations and trials. Nature Rev. Rheumatol. 6, 547–552 (2010).

    Google Scholar 

  2. Sanz, I. & Lee, F. E. B cells as therapeutic targets in SLE. Nature Rev. Rheumatol. 6, 326–337 (2010).

    Article  CAS  Google Scholar 

  3. Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260–263 (1999).

    Article  CAS  Google Scholar 

  4. Zhang, J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166, 6–10 (2001).

    Article  CAS  Google Scholar 

  5. Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).

    Article  CAS  Google Scholar 

  6. Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586–599 (2006).

    Article  CAS  Google Scholar 

  7. US Food and Drug Administration. FDA labelling information — Benlysta. FDA website [online], (2011).

  8. Wallace, D. J. et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).

    Article  CAS  PubMed Central  Google Scholar 

  9. Yee, M. et al. RBC Capital Markets Equity Research (28 Mar 2011).

    Google Scholar 

  10. Mehroti, R. et al. Human Genome Sciences (Credit Suisse Equity Research, 28 Mar 2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Iaki Sanz is at the Division of Allergy, Department of Medicine, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA.,

    Iñaki Sanz

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. ,

    Peter Kirkpatrick

Authors
  1. Iñaki Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Iñaki Sanz, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

I.S. has consulted for GlaxoSmithKline (less than $5000) and has an ongoing research collaboration with Biogen Idec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanz, I., Yasothan, U. & Kirkpatrick, P. Belimumab. Nat Rev Drug Discov 10, 335–336 (2011). https://doi.org/10.1038/nrd3436

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3436

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing